# Study to Evaluate the Safety of a Lyophilized RSV mRNA Vaccine

> **NCT07418229** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Sinovac Biotech Co., Ltd** · enrollment: 60 (estimated)

## Conditions studied

- RSV
- mRNA Vaccine

## Interventions

- **BIOLOGICAL:** Low-dose RSV mRNA vaccine
- **BIOLOGICAL:** High-dose RSV mRNA vaccine
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT07418229
- **Lead sponsor:** Sinovac Biotech Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-09
- **Primary completion:** 2026-06-30
- **Final completion:** 2027-05-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07418229

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07418229, "Study to Evaluate the Safety of a Lyophilized RSV mRNA Vaccine". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07418229. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*